

IntelGenx Technologies Corp.  
Form 8-K  
January 13, 2014

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**January 13, 2013**  
Date of Report (Date of Earliest Event Reported)

**IntelGenx Technologies Corp.**  
(Exact Name of Registrant as Specified in its Charter)

|   |   |  |
|---|---|--|
| <b>Delaware</b><br>(State or other jurisdiction of<br>incorporation)  | <b>000-31187</b><br>(Commission File<br>Number) | <b>870638336</b><br>(IRS Employer Identification<br>No.) |
| <b><u>6425 Abrams, Ville St- Laurent, Quebec, Canada H4S 1X9</u></b><br>(Address of principal executive offices) (Zip Code) |   |  |

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a -12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
-

**Item 8.01 Other Events - News Release**

**IntelGenx Announces Additional Development And Commercialization Agreement With Par Pharmaceutical, Inc. For Two More Products**

| Exhibit     | Description          |
|-------------|----------------------|
| <u>99.1</u> | <u>Press Release</u> |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGEX TECHNOLOGIES CORP.**

Dated: January 13, 2013

By: /s/ Rajiv Khosla

Rajiv Khosla

President and Chief Executive Officer

---